Dare Bioscience, INC 8-K filings

Dar Bioscience, Inc. has released a corporate presentation dated July 24, 2026, intended for use in upcoming investor meetings.

Dare Bioscience has received a notice from Nasdaq indicating its common stock is subject to delisting due to non-compliance with minimum stockholders' equity requirements.

Dare Bioscience provides a corporate presentation on July 13, 2026, outlining its current initiatives and future plans.

Dar Bioscience stockholders approved the 2022 Stock Incentive Plan amendment and ratified key corporate governance proposals.

Dar Bioscience, Inc. announced the closing of its Regulation A offering, issuing 50,000 units for $5.00 each.

Dar Bioscience announced first quarter 2026 financial results, highlighting progress in its women's health pipeline and anticipating first product revenue in June 2026.

Daré Bioscience, Inc. has released an updated corporate presentation on April 22, 2026, available on their website.

Dar Bioscience has closed a portion of its Regulation A offering, issuing 20,000 units at $5.00 per unit.

Dar Bioscience announced the reclassification of director Gregory W. Matz to balance its board classes ahead of the 2026 annual meeting.

Dar Bioscience, Inc. announced the closing of its Regulation A offering, issuing 3,470 investor units.

Dar Bioscience, a women's health biotech, reported improved operational results for 2025, driven by pipeline advancements and expects product revenue to commence in Q2 2026.

Dare Bioscience, Inc. announced the completion of a closing for its previously announced Regulation A offering, issuing 43,050 Investor Units.

Dar Bioscience, Inc. announced the availability of an updated corporate presentation on its investor relations website.

Dar Bioscience, Inc. successfully completed the initial closing of its Regulation A offering, raising capital through the sale of Series A Convertible Preferred Stock and warrants.

Dare Bioscience, Inc. has released an updated corporate presentation, now available on its investor relations website.

Dare Bioscience announced Bayer's termination of their Ovaprene license agreement, returning full commercialization rights to Dare while its Phase 3 study progresses with positive interim data and grant funding.

Dare Bioscience announced its third-quarter 2025 financial results and provided a corporate update, highlighting progress in its women's health product pipeline and near-term commercialization plans.

Dare Bioscience, Inc. announced the furnishing of a new corporate presentation for use in meetings with securities market participants.

Dar Bioscience reports Q2 2025 financial results, highlighting the Q4 2025 launch of DARE to PLAY Sildenafil Cream and positive interim Phase 3 data for Ovaprene.

Dare Bioscience, Inc. has regained compliance with Nasdaq's stockholders' equity requirement but will be subject to a mandatory one-year panel monitor with stricter delisting rules.

Dare Bioscience, Inc. announced it believes its stockholders' equity now exceeds Nasdaq's $2.5 million minimum requirement after raising approximately $16.5 million through equity sales, and intends to notify Nasdaq for a compliance determination.

Dare Bioscience, Inc. announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial for Ovaprene, its investigational monthly, hormone-free intravaginal contraceptive, with the Data Safety Monitoring Board recommending the study continue without modification.

Dare Bioscience, Inc. stockholders approved the expansion of its 2022 Stock Incentive Plan by 600,000 shares, elected three Class II directors, and ratified its independent auditor at the reconvened annual meeting on July 9, 2025.

Dare Bioscience, Inc. announced that the Nasdaq Hearings Panel approved its modified multi-step plan to regain compliance with listing requirements, though the company faces a critical deadline of August 12, 2025, to avoid delisting.

Dare Bioscience, Inc. filed a Form 8-K to announce the furnishing of a corporate presentation dated June 9, 2025, intended for use in various meetings with securities market participants.

Dar Bioscience announced its Q1 2025 financial results, highlighting a strategic shift towards commercializing multiple women's health solutions through various channels, including 503B compounding and consumer health products.

Dar Bioscience received an extension from Nasdaq to regain compliance with listing rules, contingent on meeting specific milestones and raising capital.

Dare Bioscience plans to make its proprietary Sildenafil Cream formulation available via prescription this year through 503B compounding, while also reporting its financial results for the year ended December 31, 2024.

Dare Bioscience, Inc. is at risk of being delisted from the Nasdaq Capital Market after failing to meet the minimum market value of listed securities requirement by the February 10, 2025 deadline.

Dare Bioscience, Inc. shares a corporate presentation at the BIO CEO & Investor Conference on February 10, 2025, and in meetings with securities market participants.